Expert oncologist John Heymach, MD, PhD, reviews data from the phase 3 AEGEAN trial following updates presented at the 2023 AACR annual meeting.
John Heymach, MD, PhD, MD Anderson Cancer Center
Advertisement
Articles by John Heymach, MD, PhD, MD Anderson Cancer Center
Advertisement
Latest Updated Articles
AEGEAN: A Phase 3 Trial of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab in Patients with Resectable NSCLCPublished: May 19th 2023 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
4
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
5